Clinical trial
Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of…
NCT00116935 · Scandinavian Sarcoma Group, Other · Completed
Key facts
| NCT number | NCT00116935 |
|---|---|
| Title | Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST) |
| Official title | Short (12 Months) Versus Long (36 Months) Duration of Adjuvant Treatment With the Tyrosine Kinase Inhibitor Imatinib Mesylate of Operable GIST With a High Risk of Recurrence |
| Lead sponsor | Scandinavian Sarcoma Group, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sarcoma |
| Intervention type | Drug |
| Interventions | imatinib mesylate, imatinib |
| Enrollment | 400 |
| Start date | Feb 1, 2004 |
| Primary completion | Dec 1, 2010 |
| Completion | Dec 1, 2010 |
| First posted | Jul 1, 2005 |
| Last update posted | Dec 30, 2011 |
| Countries | Sweden |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: